

Interaction Report**Report ID:****Date Produced:** 27 January 2022**Antiretroviral Treatment****Co-medications**Dolutegravir (DTG)
Doravirine/Lamivudine/ Tenofovir-DF (DOR/3TC/TDF)

Trimethoprim/Sulfamethoxazole

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions

Potential weak interaction - additional action/monitoring or dosage adjustment is unlikely to be required (YELLOW)

Doravirine/Lamivudine/ Tenofovir-DF (DOR/3TC/TDF) + Trimethoprim/Sulfamethoxazole
Coadministration has not been studied. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. No interaction is expected with doravirine or tenofovir-DF. In vitro data indicate that trimethoprim inhibits the renal transporters OCT2 and MATE1 and trimethoprim has been shown to increase lamivudine exposure by 43%. No dose adjustment is required in patients with normal renal function. Note, the bioavailability of lamivudine solution has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in liquid formulations such trimethoprim/sulfamethoxazole paediatric suspension. When possible, avoid use of sorbitol-containing medicines with lamivudine-containing medicines.

No clinically significant interaction expected (GREEN)

Dolutegravir (DTG) + Trimethoprim/Sulfamethoxazole